BACKGROUND: Previously we conducted a double-blind controlled, randomized efficacy field trial of gD-2 HSV vaccine adjuvanted with ASO4 in 8323 women. Subjects had been previously selected to be seronegative for HSV-1 and HSV-2. We found that vaccine was 82% protective against HSV-1 genital disease, but offered no significant protection against HSV-2 genital disease. METHODS: To better understand the results of the efficacy study, post-vaccination anti-gD-2 antibody concentrations from all HSV infected subjects and matched uninfected controls were measured. Three models were used to determine whether thes responses correlated with protection against HSV infection or disease. Similarly, cellular immune responses from a subset of subjects and matched controls were evaluated for a correlation with HSV protection. RESULTS: Antibodies to gD-2 correlated with protection against HSV-1 infection with higher antibody concentration associated with higher efficacy. Cellular immune responses to gD-2 did not correlate with protection. CONCLUSIONS: The protection against HSV-1 infection observed in the Herpevac Trial for Women was associated with antibodies directed against the vaccine. Clinical Trials Registration NCT00057330.
RCT Entities:
BACKGROUND: Previously we conducted a double-blind controlled, randomized efficacy field trial of gD-2 HSV vaccine adjuvanted with ASO4 in 8323 women. Subjects had been previously selected to be seronegative for HSV-1 and HSV-2. We found that vaccine was 82% protective against HSV-1 genital disease, but offered no significant protection against HSV-2 genital disease. METHODS: To better understand the results of the efficacy study, post-vaccination anti-gD-2 antibody concentrations from all HSV infected subjects and matched uninfected controls were measured. Three models were used to determine whether thes responses correlated with protection against HSV infection or disease. Similarly, cellular immune responses from a subset of subjects and matched controls were evaluated for a correlation with HSV protection. RESULTS: Antibodies to gD-2 correlated with protection against HSV-1 infection with higher antibody concentration associated with higher efficacy. Cellular immune responses to gD-2 did not correlate with protection. CONCLUSIONS: The protection against HSV-1 infection observed in the Herpevac Trial for Women was associated with antibodies directed against the vaccine. Clinical Trials Registration NCT00057330.
Authors: Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal Journal: N Engl J Med Date: 2012-01-05 Impact factor: 91.245
Authors: L Corey; A G Langenberg; R Ashley; R E Sekulovich; A E Izu; J M Douglas; H H Handsfield; T Warren; L Marr; S Tyring; R DiCarlo; A A Adimora; P Leone; C L Dekker; R L Burke; W P Leong; S E Straus Journal: JAMA Date: 1999-07-28 Impact factor: 56.272
Authors: S Kohl; E D Charlebois; M Sigouroudinia; C Goldbeck; K Hartog; R E Sekulovich; A G Langenberg; R L Burke Journal: J Infect Dis Date: 2000-01 Impact factor: 5.226
Authors: Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin Journal: N Engl J Med Date: 2002-11-21 Impact factor: 91.245
Authors: R L Ashley; F M Crisostomo; M Doss; R E Sekulovich; R L Burke; M Shaughnessy; L Corey; N L Polissar; A G Langenberg Journal: J Infect Dis Date: 1998-07 Impact factor: 5.226
Authors: David I Bernstein; Abbie R Bellamy; Edward W Hook; Myron J Levin; Anna Wald; Marian G Ewell; Peter A Wolff; Carolyn D Deal; Thomas C Heineman; Gary Dubin; Robert B Belshe Journal: Clin Infect Dis Date: 2012-10-19 Impact factor: 9.079
Authors: Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman Journal: J Virol Date: 2015-06-03 Impact factor: 5.103
Authors: Sita Awasthi; Lauren M Hook; Gokul Swaminathan; Tina M Cairns; Benjamin Brooks; Jeffrey S Smith; Noah T Ditto; Marian E Gindy; Andrew J Bett; Amy S Espeseth; Gary H Cohen; Harvey M Friedman Journal: Vaccine Date: 2019-05-29 Impact factor: 3.641
Authors: Tina M Cairns; Zhen-Yu Huang; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Anna Wald; Claude Krummenacher; Roselyn J Eisenberg; Gary H Cohen Journal: J Virol Date: 2014-08-20 Impact factor: 5.103
Authors: Chaya D Patel; Sean A Taylor; Jesse Mehrbach; Sita Awasthi; Harvey M Friedman; David A Leib Journal: J Virol Date: 2020-05-18 Impact factor: 5.103
Authors: Natalie L M Ramsey; Maria Visciano; Richard Hunte; Lip Nam Loh; Clare Burn Aschner; William R Jacobs; Betsy C Herold Journal: J Virol Date: 2020-06-16 Impact factor: 5.103
Authors: Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen Journal: J Infect Dis Date: 2019-08-09 Impact factor: 5.226
Authors: Sita Awasthi; Lauren M Hook; Norbert Pardi; Fushan Wang; Arpita Myles; Michael P Cancro; Gary H Cohen; Drew Weissman; Harvey M Friedman Journal: Sci Immunol Date: 2019-09-20